Warsaw - Delayed Quote PLN
Celon Pharma S.A. (CLN.WA)
At close: 5:04 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
171,539.00
164,394.00
161,915.00
169,559.00
135,480.00
--
Cost of Revenue
62,146.00
66,819.00
66,462.00
61,715.00
36,643.00
--
Gross Profit
109,393.00
97,575.00
95,453.00
107,844.00
98,837.00
--
Operating Expense
156,666.00
128,574.00
133,455.00
121,451.00
105,575.00
--
Operating Income
-47,273.00
-30,999.00
-38,002.00
-13,607.00
-6,738.00
--
Net Non Operating Interest Income Expense
-2,003.00
-1,725.00
-681.00
-2,039.00
-1,276.00
--
Pretax Income
-38,688.00
-19,968.00
-36,446.00
-15,087.00
-5,588.00
--
Tax Provision
6,793.00
8,156.00
2,831.00
-3,480.00
-4,671.00
--
Net Income Common Stockholders
-45,481.00
-28,124.00
-39,277.00
-11,607.00
-917.00
--
Diluted NI Available to Com Stockholders
-45,481.00
-28,124.00
-39,277.00
-11,607.00
-917.00
--
Basic EPS
-0.87
-0.55
-0.77
-0.25
-0.02
--
Diluted EPS
-0.87
-0.55
-0.77
-0.25
-0.02
--
Basic Average Shares
51,571.27
51,056.50
51,024.43
46,676.71
45,000.00
--
Diluted Average Shares
51,571.27
51,056.50
51,035.00
46,684.29
45,000.00
--
Total Operating Income as Reported
-43,745.00
-27,242.00
-37,336.00
-10,453.00
-3,673.00
--
Total Expenses
218,812.00
195,393.00
199,917.00
183,166.00
142,218.00
--
Net Income from Continuing & Discontinued Operation
-45,481.00
-28,124.00
-39,277.00
-11,607.00
-917.00
--
Normalized Income
-51,937.51
-38,204.00
-41,205.00
-11,708.55
-1,262.87
--
Interest Income
89.00
372.00
1,847.00
84.00
142.00
--
Interest Expense
2,505.00
2,662.00
1,671.00
1,553.00
667.00
--
Net Interest Income
-2,003.00
-1,725.00
-681.00
-2,039.00
-1,276.00
--
EBIT
-36,183.00
-17,306.00
-34,775.00
-13,534.00
-4,921.00
--
EBITDA
14,517.00
32,710.00
9,320.00
27,808.00
29,619.00
--
Reconciled Cost of Revenue
62,146.00
66,819.00
66,462.00
61,715.00
36,643.00
--
Reconciled Depreciation
50,700.00
50,016.00
44,095.00
41,342.00
31,767.00
--
Net Income from Continuing Operation Net Minority Interest
-45,481.00
-28,124.00
-39,277.00
-11,607.00
-917.00
--
Total Unusual Items Excluding Goodwill
7,971.00
10,080.00
1,928.00
132.00
427.00
--
Total Unusual Items
7,971.00
10,080.00
1,928.00
132.00
427.00
--
Normalized EBITDA
6,546.00
22,630.00
7,392.00
27,676.00
29,192.00
--
Tax Rate for Calcs
0.00
--
--
0.00
0.00
--
Tax Effect of Unusual Items
1,514.49
--
--
30.45
81.13
--
12/31/2019 - 2/17/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade